BioSpace News Archive

The Foundry today announced the successful completion of the first-in-human procedure with the Half Moon Medical transcatheter mitral repair technology (TMVr) at Oregon Health and Science University (OHSU) as part of an FDA-approved early feasibility study.

-- Unaudited Total Revenues of between $35.0 Million and $36.0 Million for Fourth Quarter 2020 and between $108.0 Million and $109.0 Million for the Full Year 2020 -- -- XPOVIO® (selinexor) Unaudited Net Product Sales of between $20.0 Million and $20.5 Million for Fourth Quarter 2020 and between $76.0 Million and $76.5 Million for the Full Year 2020 -- -- Commercial Launch of XPOVIO in Expanded Multiple Myeloma Indication Fully Underway --

Unchained Labs, the life sciences company that’s all about getting researchers the right tool for the job, launched its new mRNA vaccine application on Stunner.

Charles River Laboratories International, Inc. announced that it will virtually present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12th, at 10:00 a.m. EST.

Amyris, Inc., a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands and a top supplier of sustainable and natural ingredients, announced that it will be launching a new clean haircare brand through a partnership with Jonathan Van Ness, American hairdresser, television personality, podcast host, actor and author.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually between January 11-14, 2021.

ReCode Therapeutics™ (ReCode) (the Company), a private biopharmaceutical company pioneering disease-modifying medicines for the treatment of life-limiting respiratory diseases, today announced that David Lockhart, CEO, will present virtually at the 39th Annual J.P. Morgan Healthcare Conference at 5:30 p.m. ET on Wednesday, January 13, 2021.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CK-3773274 (CK-274) for the treatment of symptomatic hypertrophic cardiomyopathy (HCM). CK-274 is a next-generation cardiac myosin inhibitor in development for the potential treatment of HCM.

-- Presenting at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021 at 10:50 a.m. Eastern/7:50 a.m. Pacific --

DexCom, Inc., the leader in continuous glucose monitoring, reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2020 to meet or exceed $567 million, an increase of 23% over the fourth quarter of 2019.